Loading insider details...
Beta
Latest Form 4 (Jun 15, 2026): Grant/Award of 2,700 QNCX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 2,700 | n/a |
| May 19, 2026 | EXELIXIS, INC. (EXEL) | Tax Withholding | 40,892 | $2.09M |
| Mar 3, 2026 | EXELIXIS, INC. (EXEL) | Grant/Award | 52,018 | n/a |
| Feb 19, 2026 | EXELIXIS, INC. (EXEL) | Sale | 34,278 | $1.47M |
| Jan 21, 2026 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 21,810 | n/a |
| Jan 17, 2026 | EXELIXIS, INC. (EXEL) | Grant/Award | 149,474 | n/a |
| Jun 6, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| May 17, 2025 | EXELIXIS, INC. (EXEL) | Tax Withholding | 41,422 | $1.85M |
| Mar 31, 2025 | EXELIXIS, INC. (EXEL) | Grant/Award | 170,009 | n/a |
| Mar 1, 2025 | EXELIXIS, INC. (EXEL) | Grant/Award | 59,648 | n/a |